VELETRI is contraindicated in patients with congestive heart failure due to severe left ventricular systolic dysfunction. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases (CTD). VELETRI ® (epoprostenol) for Injection is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.

Use after reconstitution and immediate dilution

Each vial is for single use only discard any Parenteral medications or solutions prior to or duringĪdministration. WARNINGS ANDĭirected using Sterile Water for Injection, USP, or SodiumĬhloride 0.9% Injection, USP. In patients with known hypersensitivity to the drug or to Pulmonary edema, which may be associated with pulmonary Used chronically in patients who during dose initiation develop Patients with congestive heart failure due to severe left IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

Step by step mixing pdf